Other than ibrutinib, patients with M-CLL, devoid of TP53 aberrations and healthy adequate to tolerate FCR therapy, should be very good candidates for the latter, Along with the advantage staying this treatment may be done in six months even though ibrutinib need to be taken indefinitely. This feature will be https://frankf196xem2.bloggactivo.com/profile